Firms ally to develop deuterium-based drugs for cancer, inflammation

Concert Pharmaceuticals granted Celgene the right to use its deuterated chemical entity technology to develop new deuterium-modified small compounds for cancer and inflammation. Concert will get an upfront payment and more than $300 million in possible milestone fees for each program selected for development, plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC